216 related articles for article (PubMed ID: 37515491)
1. Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosis.
Betts M; Fahrbach K; Neupane B; Slim M; Sormani MP; Cutter G; Debray TP; Rock M
J Comp Eff Res; 2023 Aug; 12(8):e220132. PubMed ID: 37515491
[No Abstract] [Full Text] [Related]
2. Methods for the inclusion of real-world evidence in network meta-analysis.
Jenkins DA; Hussein H; Martina R; Dequen-O'Byrne P; Abrams KR; Bujkiewicz S
BMC Med Res Methodol; 2021 Oct; 21(1):207. PubMed ID: 34627166
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Does type of funding affect reporting in network meta-analysis? A scoping review of network meta-analyses.
Veroniki AA; Wong EKC; Lunny C; Martinez Molina JC; Florez ID; Tricco AC; Straus SE
Syst Rev; 2023 May; 12(1):81. PubMed ID: 37149700
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
[TBL] [Abstract][Full Text] [Related]
6. Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs.
Thieffry S; Klein P; Baulac M; Plumb J; Pelgrims B; Steeves S; Borghs S
Epilepsia; 2020 Apr; 61(4):595-609. PubMed ID: 32201951
[TBL] [Abstract][Full Text] [Related]
7. Prior Choices of Between-Study Heterogeneity in Contemporary Bayesian Network Meta-analyses: an Empirical Study.
Rosenberger KJ; Xing A; Murad MH; Chu H; Lin L
J Gen Intern Med; 2021 Apr; 36(4):1049-1057. PubMed ID: 33403620
[TBL] [Abstract][Full Text] [Related]
8. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.
Lees S; Dicker M; Ku JE; Chaganti V; Mew-Sum M; Wang N; Smith A; Oldmeadow C; Goon WL; Bevan M; Lang D; Hinwood M
BMJ Open; 2021 Nov; 11(11):e051509. PubMed ID: 34728450
[TBL] [Abstract][Full Text] [Related]
9. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
10. Exploiting relationships between outcomes in Bayesian multivariate network meta-analysis with an application to relapsing-remitting multiple sclerosis.
Waddingham E; Matthews PM; Ashby D
Stat Med; 2020 Oct; 39(24):3329-3346. PubMed ID: 32672370
[TBL] [Abstract][Full Text] [Related]
11. Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis.
Dang YL; Yong VT; Sharmin S; Perucca P; Kalincik T
Mult Scler; 2023 May; 29(6):657-667. PubMed ID: 36802988
[TBL] [Abstract][Full Text] [Related]
12. Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications.
Wong EK; Lachance CC; Page MJ; Watt J; Veroniki A; Straus SE; Tricco AC
BMJ Open; 2019 Sep; 9(9):e031138. PubMed ID: 31492792
[TBL] [Abstract][Full Text] [Related]
13. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B
Mult Scler Relat Disord; 2023 Jan; 69():104459. PubMed ID: 36565573
[TBL] [Abstract][Full Text] [Related]
14. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
17. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
18. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
19. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
